2008 - Review: Interferon and nucleoside/tide analogues reduce risk for hepatocellular cancer in patients with chronic hepatitis B

Sherker, Averell H.
April 2009
ACP Journal Club;4/21/2009, Vol. 150 Issue 4, p9
Academic Journal
The article discusses, studies which tried to find out whether interferon and nucleoside/tide analogues reduce risk for hepatocellular cancer (HCC) in patients with chronic hepatitis B virus (HBV) infection. The meta-analysis conformed that interferon and nucleoside/tide analogues reduces risk for HCC more than placebo or no treatment.


Related Articles

  • AASLD Updates Chronic Hepatitis B Recommendations. HUNTZINGER, AMBER // American Family Physician;2/15/2009, Vol. 79 Issue 4, p338 

    The article focuses on the updated chronic hepatitis B virus (HBV) infection recommendations from the American Association for the Study of Liver Diseases (AASLD), which include the preferred diagnostic, therapeutic, and preventive approaches to chronic HBV. It notes that chronic HBV infection...

  • Antiviral Activity of Bay 41-4109 on Hepatitis B Virus in Humanized Alb-uPA/SCID Mice. Brezillon, Nicolas; Brunelle, Marie-Noëlle; Massinet, Hé lène; Giang, Eric; Lamant, Cé line; DaSilva, Lucie; Berissi, Sophie; Belghiti, Jacques; Hannoun, Laurent; Puerstinger, Gherard; Wimmer, Eva; Neyts, Johan; Hantz, Olivier; Soussan, Patrick; Morosan, Serban; Kremsdorf, Dina // PLoS ONE;2011, Vol. 6 Issue 12, p1 

    Current treatments for HBV chronic carriers using interferon alpha or nucleoside analogues are not effective in all patients and may induce the emergence of HBV resistant strains. Bay 41-4109, a member of the heteroaryldihydropyrimidine family, inhibits HBV replication by destabilizing capsid...

  • Nucleoside Analogs as Anti-HBV Agents. Xiao-Xiong Zhou; Littler, Eddy // Current Topics in Medicinal Chemistry;May2006, Vol. 6 Issue 9, p851 

    Chronic hepatitis B virus (HBV) infection affects about 400 million people worldwide. The development of nucleoside analogs that inhibit HBV polymerase provides an important approach for treating HBV infection. The approval of lamivudine, adefovir and entecavir represents a cornerstone of...

  • Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma? Thursz, Mark; Brown, Ashley // Gut;Aug2011, Vol. 60 Issue 8, p1025 

    In this article, the authors discuss the effectiveness of antiviral therapy for chronic hepatitis B in preventing the development of hepatocellular carcinoma (HCC). The authors cite the differences between the 2004 study of Y. F. Liaw and colleagues and G. V. Papatheodoridis and colleagues which...

  • Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon γ signalling pathway. Hsuan-Hao Huang // Gut;Jan2011, Vol. 60 Issue 1, p99 

    OBJECTIVE: High viraemia of hepatitis B virus (HBV) influences all phases in the development of hepatocellular carcinoma (HCC). This study was designed to estimate the overall contribution of host genetics to HBV viraemia, and investigate the influence of common single-nucleotide polymorphisms...

  • Hepatitis B virus S gene escape mutants. Purdy, Michael A. // Asian Journal of Transfusion Science;Jul-Dec2007, Vol. 1 Issue 2, p62 

    Hepatitis B virus (HBV) can be classified into nine immunological subtypes or eight genotypes. The most prevalent genotypes in Asia are genotypes B and C. HBV is transmitted parenteraly and can produce either asymptomatic or symptomatic disease. Although the consequences of acute hepatitis B can...

  • Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Wong, David K.H.; Cheung, Angela M.; O'Rourke, Keith; Naylor, C. David; Detsky, Allan S.; Heathcote, Jenny; Wong, D K; Cheung, A M; O'Rourke, K; Naylor, C D; Detsky, A S; Heathcote, J // Annals of Internal Medicine;8/15/93, Vol. 119 Issue 4, p312 

    Purpose: To determine whether alpha-interferon is effective in terminating viral replication and in eradicating the carrier state in patients with chronic hepatitis B virus (HBV) infection.Data Sources: Randomized controlled studies published in the English literature...

  • Genotype Mixtures of Hepatitis B Virus in Patients Treated with Interferon. Hannoun, Charles; Krogsgaard, Kim; Horal, Petr; Lindh, Magnus // Journal of Infectious Diseases;9/15/2002, Vol. 186 Issue 6, p752 

    Little is known about coinfection among several hepatitis B virus (HBV) genotypes, although previous reports of recombination and genotype shifts indicate that this should occur. In the present study, we designed a method to identify mixtures of genotype A and another genotype, regardless of...

  • Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection. Yuki, Nobukazu; Nagaoka, Takayuki; Nukui, Kazuhiko; Omura, Masao; Hikiji, Kazumasa; Kato, Michio // Journal of Gastroenterology;2008, Vol. 43 Issue 6, p457 

    The virologic impact of adding interferon to antiviral nucleoside therapy was studied in Japanese patients having perinatally transmitted hepatitis B virus (HBV) genotype C. Sixty-four patients including 41 positive for hepatitis B e antigen (HBeAg) were assigned to receive either (1) a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics